Table 3.

Medical treatment of mRCC according to EAU guidelines.

IMDC risk group	First-line therapy	Second-line therapy	Third line therapy
Favorable	Sunitinib or pazopanib	Cabozantinib or nivolumab	Cabozantinib or nivolumab
Intermediate and poor	Ipilimumab+nivolumab Cabozantinib, sunitinib or pazopanib	Cabozantinib or other VEGF targeted therapy VEGF targeted therapy or nivolumab	Cabozantinib or other targeted therapy Other targeted therapy or nivolumab

European Association of Urology guidelines accessed at https://uroweb.org/guideline/renal-cell-carcinoma/#7 on 6th May 2019. VEGF, vascular endothelial growth factor; IMDC, International Metastatic RCC Database Consortium.